Merck & Co., too, is on the hunt.
“We actually tried to consummate some deals; they haven’t worked because we haven’t had a willing seller, or the asset was too robustly competitive because it was a late-stage asset,” Merck CEO Ken Frazier said at the conference. “But, broadly speaking I think with the valuations coming down, it creates more possibilities.”